February 17th, 2021 Comments Off on Management
Management
- Fb
- Tw
- Pin
Recent Posts
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
- Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
- Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
- Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
- Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
